OpSens Announces 510(K) Submission to U.S. FDA for New Guidewire for the TAVR Procedure
13 December 2021OpSens Announces 510(K) Submission to U.S. FDA for New Guidewire for the TAVR Procedure Quebec City, Quebec, December 13, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that it has filed a 510(k) submission with the U.S….
OpSens to Present at the Lytham Partners Winter 2021 Investor Conference Presentation at 11 AM (ET), Monday December 13, 2021
7 December 2021OPSENS TO PRESENT AT THE LYTHAM PARTNERS WINTER 2021 INVESTOR CONFERENCE Presentation at 11 AM (ET), Monday December 13, 2021 Quebec, Quebec, December 7, 2021 – OpSens inc. («OpSens» or the «Company») (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, announced today that it will be…